CDSCO Advisory May 2026 India's CDSCO issued a public notice on May 18, 2026 placing injectable glutathione under regulatory scrutiny, partly due to reports associated with unsupervised cosmetic IV use
Oral semaglutide may show slightly slower initial results than injectable semaglutide due to absorption differences, though both achieve similar long-term outcomes
En realidad, slo conocemos los datos humanos cuando algo sale mal, apunt
Such results suggest that GLP1 may be able to delay or offset the death of beta cells in conditions such as T1DM
Why Real World Results Vary Side effects and stopping behavior can also change the picture
For Ozempic, common side effects often involve gastrointestinal issues such as nausea, vomiting, and diarrhea